WO2010137036A3 - Japanese encephalitis vaccine and method of manufacturing the same - Google Patents

Japanese encephalitis vaccine and method of manufacturing the same Download PDF

Info

Publication number
WO2010137036A3
WO2010137036A3 PCT/IN2010/000343 IN2010000343W WO2010137036A3 WO 2010137036 A3 WO2010137036 A3 WO 2010137036A3 IN 2010000343 W IN2010000343 W IN 2010000343W WO 2010137036 A3 WO2010137036 A3 WO 2010137036A3
Authority
WO
WIPO (PCT)
Prior art keywords
japanese encephalitis
same
manufacturing
vaccine
encephalitis vaccine
Prior art date
Application number
PCT/IN2010/000343
Other languages
French (fr)
Other versions
WO2010137036A2 (en
Inventor
Rajesh Jain
Milind V Galgalkar
Kapil Maithal
Sudhanshu Vrati
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of WO2010137036A2 publication Critical patent/WO2010137036A2/en
Publication of WO2010137036A3 publication Critical patent/WO2010137036A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a novel Japanese encephalitis vaccine and a novel process for making the same. The invention in particular relates to a Japanese encephalitis virus strain P20778 vaccine, wherein the viral adaptation and propagation is carried out in a medium which is free of serum and additives of animal origin. The virus may be propagated particularly in Vero cell line.
PCT/IN2010/000343 2009-05-25 2010-05-21 Novel japanese encephalitis vaccine and method of manufacturing the same WO2010137036A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1064DE2009 2009-05-25
IN1064/DEL/2009 2009-05-25

Publications (2)

Publication Number Publication Date
WO2010137036A2 WO2010137036A2 (en) 2010-12-02
WO2010137036A3 true WO2010137036A3 (en) 2011-05-26

Family

ID=42668852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000343 WO2010137036A2 (en) 2009-05-25 2010-05-21 Novel japanese encephalitis vaccine and method of manufacturing the same

Country Status (3)

Country Link
KR (1) KR20120027381A (en)
AR (1) AR076924A1 (en)
WO (1) WO2010137036A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101484605B1 (en) * 2012-07-25 2015-01-20 대한민국 Inactivated vaccine composition for Japanese Encephalitis comprising Japanese encephalitis virus KV1899 strain antigen inactivated by binaryethyleneimine and swine GM-CSF recombinant protein
CN102925414B (en) * 2012-10-19 2014-09-24 江苏省农业科学院 Swine Japanese encephalitis virus strain and application thereof
IN2013CH04135A (en) * 2013-09-14 2015-08-14 Bharat Biotech Int Ltd
WO2023204559A1 (en) * 2022-04-20 2023-10-26 대한민국(질병관리청 국립보건연구원장) High-titer japanese encephalitis virus genotype 5 and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004803A1 (en) * 1995-08-01 1997-02-13 Pasteur Merieux Serums & Vaccins Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
WO1999011762A1 (en) * 1997-08-28 1999-03-11 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
EP1057889A1 (en) * 1998-10-05 2000-12-06 The Research Foundation for Microbial Diseases of Osaka University Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
WO2009030676A2 (en) * 2007-09-03 2009-03-12 Intercell Ag Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004803A1 (en) * 1995-08-01 1997-02-13 Pasteur Merieux Serums & Vaccins Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
WO1999011762A1 (en) * 1997-08-28 1999-03-11 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
EP1057889A1 (en) * 1998-10-05 2000-12-06 The Research Foundation for Microbial Diseases of Osaka University Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
WO2009030676A2 (en) * 2007-09-03 2009-03-12 Intercell Ag Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUGAWARA KEISHIN ET AL: "Development of Vero cell-derived inactivated Japanese encephalitis vaccine.", BIOLOGICALS, vol. 30, no. 4, December 2002 (2002-12-01), pages 303 - 314, XP002599708, ISSN: 1045-1056 *
VRATI SUDHANSHU: "Comparison of the genome sequences and the phylogenetic analyses of the GP78 and the Vellore P20778 isolates of Japanese encephalitis virus from India", JOURNAL OF BIOSCIENCES (BANGALORE), vol. 25, no. 3, September 2000 (2000-09-01), pages 257 - 262, XP002599707, ISSN: 0250-5991 *

Also Published As

Publication number Publication date
WO2010137036A2 (en) 2010-12-02
AR076924A1 (en) 2011-07-20
KR20120027381A (en) 2012-03-21

Similar Documents

Publication Publication Date Title
WO2012149339A3 (en) Quantification of a minority nucleic acid species
MY151119A (en) Duck embryonic derived stem cell lines for the production of viral vaccines
WO2013027999A3 (en) D-psicose 3-epimerase mutant with improved thermal stability, and continuous production of d-psicose using same
EA201491087A1 (en) METHODS OF PRODUCING ENERGY PRODUCTS
MX2011013951A (en) Methods for agrobacterium-mediated transformation of sugar cane.
WO2010033906A3 (en) Efficient induction of pluripotent stem cells using small molecule compounds
WO2012072096A8 (en) Method for cellular rna expression
MX346700B (en) Method for improving the yield of a polypeptide.
WO2009038416A3 (en) Plant stem cell line derived from quiescent center and method for isolating the same
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
MX2012002614A (en) Novel method for preparing precipitated silica.
MX2012013027A (en) Improved methods for preparing squalene.
WO2010137036A3 (en) Japanese encephalitis vaccine and method of manufacturing the same
MX350421B (en) Rabies virus like particle production in plants.
WO2009099877A3 (en) Closterovirus vectors and methods
DE602008000176D1 (en) Process for the conversion of glucose into anilines by microorganisms
IN2014CN03077A (en)
WO2010052214A3 (en) Novel method
MX2010005701A (en) Method for producing vaccinal viral strain of a virus of the reoviridae family.
MX354838B (en) Method for preparing precipitated silica.
WO2011014416A3 (en) High yield yellow fever virus strain with increased propagation in cells
WO2011090957A3 (en) Process of preparing a particle
WO2009006446A3 (en) Methods for cloning small rna species
WO2011109612A3 (en) Method for selecting an ips cell
WO2010058427A3 (en) Process for production and purification of polymyxin b sulfate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731817

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20117030728

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10731817

Country of ref document: EP

Kind code of ref document: A2